At the time of writing, Upexi Inc [UPXI] stock is trading at $3.26, up 2.03%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The UPXI shares have gain 25.38% over the last week, with a monthly amount drifted -70.97%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Upexi Inc [NASDAQ: UPXI] stock has seen the most recent analyst activity on June 16, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight but kept the price target unchanged to $16 for it.
For the past year, the stock price of Upexi Inc fluctuated between $1.90 and $22.57. Upexi Inc [NASDAQ: UPXI] shares were valued at $3.26 at the most recent close of the market.
Analyzing the UPXI fundamentals
Gross Profit Margin for this corporation currently stands at -0.02% with Operating Profit Margin at 0.93%, Pretax Profit Margin comes in at 0.98%, and Net Profit Margin reading is 1.02%. To continue investigating profitability, this company’s Return on Assets is posted at -1.49, Equity is -5.25 and Total Capital is -4.82. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.45.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.97 points at the first support level, and at 2.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.50, and for the 2nd resistance point, it is at 3.74.
Ratios To Look Out For
It is important to note that Upexi Inc [NASDAQ:UPXI] has a current ratio of 0.37. Further, the Quick Ratio stands at 0.24, while the Cash Ratio is 0.02.
Transactions by insiders
Recent insider trading involved MARSHALL ALLAN, Chief Executive Officer, that happened on Apr 17 ’25 when 0.66 million shares were purchased. Chief Financial Officer, Norstrud Andrew James completed a deal on Apr 17 ’25 to buy 43860.0 shares. Meanwhile, Director Salkind Gene bought 0.24 million shares on Apr 17 ’25.
